CJC-1295 No DAC + Ipamorelin
A blend of two compounds studied for effects on growth-hormone signaling: CJC-1295 and ipamorelin.
Whole vial: 10 mg Vial math ↓
Why people look it up
This blend is discussed because both named ingredients affect growth-hormone signaling. People then speculate about recovery, sleep, and body composition.
Growth-hormone signals from individual ingredientsLIMITED HUMAN EVIDENCE
Human studies measured hormone signals for separate ingredients; the CJC-1295 study used a different, DAC-containing form. Read source ↗
Muscle gain or fat loss from this blendINSUFFICIENT EVIDENCE
Hormone changes in separate ingredient studies do not prove a body-composition benefit from the combined vial. Read source ↗
Better sleep or recoveryCOMMUNITY / ANECDOTAL
These are commonly reported goals, without a controlled human outcome study of this blend. Read source ↗
The labels show the evidence for each claim. Open a row for its source.
Dosage at a glance
Dosage source summary
- Lower example
- 100 mcg each
- Middle example
- 200 mcg each
- Higher example
- 250–300 mcg each
- How often
- Once daily in the published example
- Time on / time off
- The chart does not establish an agreed break schedule.
- Route
- Subcutaneous in that chart
Per ingredient: CJC-1295 No DAC + ipamorelin in a 1:1 blend. Not the total blend amount and not interchangeable with DAC forms.
These source amounts do not establish a safe human dose for a research vial.
Sources & individual reports
- PeptideDosages published chart; reviewed October 18, 2026
Per ingredient: CJC-1295 No DAC + ipamorelin in a 1:1 blend. Not the total blend amount and not interchangeable with DAC forms. Source check: 2026-10-18.
Source coverage: 2 reviewed public accounts. Separate examples, not a representative sample.
Report 1 ↗Secondhand / firsthand status unclear
- Amount reported
- 100 mcg of each named ingredient
- How often reported
- once daily before bed
- Reported duration / cycle
- about six weeks
- Route (how it was taken)
- not stated
What the account says: Poster reported one IGF-1 value before and after; no controlled comparison or independent product testing was supplied.
Product match & source details
Product match: The reported products and blend ratio were not verified as the same as this listed combination.
r/Peptidesource post about a subject · Posted: date not independently verified · Reviewed: 2026-10-03.
Report 2 ↗First-person account
- Amount reported
- 150 mcg CJC-1295 No DAC plus 200 mcg ipamorelin each time
- How often reported
- five days weekly; two days off
- Reported duration / cycle
- three weeks by original post
- Route (how it was taken)
- injection; precise route not stated
What the account says: Poster described better sleep and slightly faster workout recovery but also substantial daytime sleepiness. No controlled attribution or vial testing.
Product match & source details
Product match: Separate No DAC CJC and ipamorelin use was described; seller blend not verified.
r/Peptidesource firsthand post · Posted: 2024-07-26 · Reviewed: 2026-10-03.
How much agreement is there? Two checked accounts describe different formulations or goals. One sleep/recovery account also reported substantial sleepiness; no typical range is established.
Public sources last reviewed: 2026-10-03. Product identity and reported results were not independently verified. Source method →
Evidence, sources & vial math
What the research actually showsHuman studies, evidence limits and mechanisms
What has actually been studied?
Small human studies measured hormone release for individual compounds. A frequently cited CJC-1295 study used the long-acting DAC form, not this No DAC blend. Those hormone measurements are not proof of recovery or muscle benefits.
Evidence limits: The exact contribution of each blend ingredient, the ratio in this vial, and a tested human regimen for this combination are not established here.
Product status: Research-vial listings are not FDA-approved medicines. Approved-use labels on this page refer only to the named finished prescription product.
Human research
No human outcome study of this exact No DAC CJC-1295 plus ipamorelin blend was extracted in this review. Published human hormone measurements for CJC-1295 with DAC and for ipamorelin concern separate ingredients and do not establish sleep, recovery, body-composition, or safety outcomes for the mixture.
Reviewed cited studies and the linked product or regulator documentation; absence of an extracted trial is not proof that no study exists.
Study and prescription-product amounts describe those sources. They do not select an amount for an online research vial.
How researchers think it might work
The two named ingredients are discussed because they stimulate growth-hormone release through different signaling pathways. That does not establish how the combined No DAC vial behaves in a person.
Show scientific explanation
CJC-1295 with DAC activated the growth-hormone releasing-factor receptor in animal work; ipamorelin stimulated growth-hormone release through a growth-hormone secretagogue pathway. These studies concern separate compounds, and the cited CJC form has DAC, unlike the listed blend. Read supporting source ↗
Vial & syringe mathTurn the vial total and liquid volume into concentration and syringe units
Vial & syringe math
Change the vial total and final liquid volume to see what each U-100 syringe mark represents.
The starting 1 mL is a math example. Enter your final mixed volume to update the numbers.
100 U-100 syringe units = 1 mL. These results assume the labeled amount is evenly mixed through the final liquid volume.
Continue in the calculator →About this listingResearch-use-only status, seller names and additional background
A research material is not intended for human use. Its name or lab report does not establish suitability for a person. What research use only means →
Compiled by PeptideWhy · Scientific sources last checked 2026-10-03 · Editorial policy · Corrections